[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566655":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":32,"centralContacts":37,"locations":45,"responsibleParty":81,"collaborators":83,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":96,"maxAge":28,"enrollmentInfo":97,"targetDuration":28,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":69,"whyStopped":28,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Cyclosporine A (CsA) 0.1%","EXPERIMENTAL","After one week of hourly natamycin eye drops the participants in this arm will use this drop four times a day for one month then twice a day for one month.",[13],"Drug: Cyclosporine A",{"label":15,"type":10,"description":11,"interventionNames":16},"Cyclosporine A (CsA) 2%",[13],{"label":18,"type":19,"description":11,"interventionNames":20},"Placebo","PLACEBO_COMPARATOR",[21],"Other: Placebo Comparator: Placebo",[23,29],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Cyclosporine A","Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.",[9,15],null,{"type":6,"name":30,"description":26,"armGroupLabels":31,"otherNames":28},"Placebo Comparator: Placebo",[18],[33],{"name":34,"affiliation":35,"role":36},"Gerami D Seitzman, MD","UCSF Proctor Foundation","PRINCIPAL_INVESTIGATOR",[38,42],{"name":34,"role":39,"phone":40,"phoneExt":28,"email":41},"CONTACT","4154761442","gerami.seitzman@ucsf.edu",{"name":43,"role":39,"phone":28,"phoneExt":28,"email":44},"Thomas Lietman, MD","tom.lietman@ucsf.edu",[46,67],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"University of California, San Farncisco","NOT_YET_RECRUITING","San Francisco","California","94143","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-122.41942,37.77493,{"lat":58,"lon":57},[61,63],{"name":34,"role":39,"phone":62,"phoneExt":28,"email":41},"415-476-1442",{"name":64,"role":39,"phone":65,"phoneExt":28,"email":66},"Brianna K Colado, BA","5593492629","brianna.colado@ucsf.edu",{"facility":68,"status":69,"city":70,"state":71,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":28,"geoPoint":28,"contacts":75},"Aravind Eye Institute","RECRUITING","Pondicherry","Tamil Nadu","605 007","India","IN",[76,79],{"name":77,"role":39,"phone":28,"phoneExt":28,"email":78},"Josephine Christy, MD","josephine@aravind.org",{"name":80,"role":39,"phone":28,"phoneExt":28,"email":28},"Kunal Mandlik, MD",{"type":82,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[84,86],{"name":85,"class":6},"Aravind Eye Hospitals, India",{"name":87,"class":6},"Aravind Eye Care System","100566655","phase-3-fungal-ulcer-treatment-augmented-with-natamycin-and-cyclosporine-a-100566655",false,"NCT06658002","Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A","FANCY","Inclusion Criteria:\n\n* Inclusion is based on presenting acuity, not ulcer size.\n* Inclusion of 20\u002F40 = 6\u002F12 = 0.3 Log MAR and 20\u002F400 = 3\u002F60 = +1.3 Log MAR.\n* Smear or culture positive for fungal keratitis, any length.\n* Age 18 years.\n* Willing to participate in study.\n\nExclusion Criteria:\n\n* Co-infection with bacterial or viral keratitis.\n* Corneal perforation.\n* Requiring therapeutic keratoplasty for fungal keratitis.\n* Unwilling or unable to follow up (e.g., living too far from hospital).\n* Presenting acuity better than 20\u002F40 = 6\u002F12 = 0.3 Log MAR or worse than 20\u002F400 = 3\u002F60 = +1.3 Log MAR.\n* Subjects taking cyclosporine at any concentration on presentation.\n* Acuity worse than 20\u002F200 = 6\u002F60 = +1.0 Log MAR in unaffected eye.\n* Pregnant women.\n* Penetrating Keratoplasty.\n* Presents with a 0-7 day history of topical steroid.","ALL","18 Years",{"count":98,"type":99},150,"ESTIMATED","INTERVENTIONAL",[102],"PHASE3","The goal of this clinical trial is to learn if adjunctive topical Cyclosporine A eye drops combined with standard of care topical Natamycin treatment improves vision outcomes in patients with fungal keratitis.",[105,106],"Fungal Keratitis","Corneal Ulcer",[106,25,105,108],"Fungal Corneal Ulcer","2026-06-03",{"date":111,"type":112},"2026-06-05","ACTUAL",{"date":114,"type":112},"2025-09-01",{"date":116,"type":99},"2027-09-01",{"name":5,"class":6},2]